CYCN Average Annual Return Since 2019
Growth of $10,000.00
Without Dividends Reinvested Into CYCN


Also see:
CYCN stock yearly return 2020
CYCN stock yearly return 2021
CYCN YTD return
Compare CYCN average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 03/19/2019
End date: 12/07/2022
Start price/share: $13.51
End price/share: $0.70
Dividends collected/share: $0.00
Total return: -94.82%
CYCN Average Annual Return: -54.85%
Starting investment: $10,000.00
Ending investment: $517.84
Years: 3.72


CYCN average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments that restore cognitive function. Co.'s lead asset, CY6463, is central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGc) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), Cognitive Impairment Associated with Schizophrenia (CIAS), and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). CY6463 is the main of its CNS portfolio with ongoing clinical programs in ADv, CIAS, and MELAS. Co.'s CNS asset, CY3018, is intended to expand the potential of sGC simulation for the treatment of disorders of the CNS. The CYCN average annual return since 2019 is shown above.

The Average Annual Return on the CYCN average annual return since 2019 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether CYCN average annual return since 2019 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the CYCN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree CYCN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cyclerion Therapeutics (CYCN) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CYH Average Annual Return
CYRX Average Annual Return
CYT Average Annual Return
CYTH Average Annual Return
CYTK Average Annual Return
DARE Average Annual Return
DAWN Average Annual Return
DBTX Average Annual Return
DCPH Average Annual Return
DCTH Average Annual Return
More Healthcare companies »

 

CYCN Average Annual Return Since 2019 | www.AverageAnnualReturn.com | Copyright © 2021 - 2022, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.